Day: November 3, 2022

On June 16, 1980, Quintanilla Almacro, Eliseo published a patent.Safety of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Trimethoprim lactate. And the patent contained the following:

The title compound (I lactate) [23256-42-0] was prepared by addition of lactic acid in CHCl3 to the free base to increase the bioavailability of I, for example, from suppositories. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Safety of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to trimethoprim lactate, Pharmaceuticals: Formulation and Compounding and other aspects.Safety of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 28, 2020, Tang, Fayin published a patent.Application of 23256-42-0 The title of the patent was The preparation method of a Florfenicol powder for improving water solubility. And the patent contained the following:

The invention relates to the preparation method of a florfenicol powder for improving water solubility as well as aand an applications. The powder is composed of the following components in parts by weight: 10 parts of florfenicol powder, 3-5 parts of citric acid, 2-3 parts of polyvinylpyrrolidone PVPK30, 50-60 parts of lactose, 2-4 parts of sodium lauryl sulfate, 5-7 parts of polyethylene glycol 6000, 2-3 parts of trimethoprim lactate and 2-4 parts of palm oil. Polyethylene glycol 6000, citric acid, polyvinylpyrrolidone PVPK30, lactose, sodium dodecyl sulfate and the palm oilare adopted and various components are synergetic to improve water solubility of florfenicol and trimethoprim lactate, so that the curative effect of the florfenicol powder is optimal. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Application of 23256-42-0

The Article related to florfenicol water solubility, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On September 21, 2016, Yang, Caiyun published a patent.Related Products of 23256-42-0 The title of the patent was Compound care agent for treating chronic pyelonephritis and preparation method thereof. And the patent contained the following:

The present invention discloses a compound care agent for treating chronic pyelonephritis and preparation method thereof. The compound care agent for treating chronic pyelonephritis comprises sulfamethazine, trovafloxacin mesylate, clavulanate potassium, coated aldehyde starch oxide, imipenem, finasteride, tocopheryl acetate, coptisine, proglumetacin dipeptide, colloidal bismuth subcitrate, demetionine 1,4-butanedisulfonate, trimethoprim lactate, and vitamin C. The compound care agent of the present invention has antibacterial anti-inflammatory, nourishing liver and kidney, Qi and blood, and detoxification effects, and can effectively eliminate inflammation, repair renal function, promote kidney metabolism, and improve the immunity of the patients. Proved by clin., the compound agent of the invention for the treatment of chronic pyelonephritis, has obvious curative effect, high safety, low side effects, and good long term application prospect. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Related Products of 23256-42-0

The Article related to care agent chronic pyelonephritis, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 26, 2016, Zhang, Ronghao; Shao, Zhigang; Hou, Qiang published a patent.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Medicine for treating salpingitis of laying poultry. And the patent contained the following:

The present invention discloses a medicine for treating salpingitis of laying poultry, which comprises raw materials by weight part: Scutellaria baicalensis 6-8, Paeonia suffruticosa 5-10, Panax japonicus 3-5, Agrimonia pilosa 5-7, Corydalis yanhusuo 7-8, Radix Paeoniae Rubra 4-6, Herba Epimedii 6-8, Cnidium monnieri 2-4, Hordeum vulgare 6-10, medicated leaven 8-10, Melia toosendan 2-4, Euryale ferox 5-8, Luffa cylindrica 12-16, Cuscuta chinensis 6-10, Manis pentadactyla 2-4, Clausena excavata 4-6, Solidago decurens 6-8, Trollius macropetalus 1-3, amoxicillin 80-100, ciprofloxacin 80-100, lactic acid TMP 20-25, anhydrous sodium sulfate 650-700, and glucose powder 120-150. The invention has scientific medicines compatibility, simple administration in combination with feed, lower cost, no drug residue and toxic side effect. Combination of all medicines has effects such as effectively clearing heat and detoxicating, replenishing qi to invigorate the spleen, promoting blood circulation and hemostasis, and significant therapeutic effect to salpingitis of oviparous poultries, which effectively improves egg laying rate of laying birds, greatly increases the economic benefit of farmer. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to medicine salpingitis laying poultry, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 31, 2014, Borodkin, G. I.; Elanov, I. R.; Shubin, V. G. published an article.Quality Control of 6-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was Eco-friendly fluorination of 6-methyl- and 1,3,6-trimethyluracils in water. And the article contained the following:

We examined the reaction of 6-methyl- and 1,3,6-trimethyluracils with F-TEDA-BF4, 4-chloromethyl-1-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate), in water. The experimental process involved the reaction of 6-Methylpyrimidine-2,4(1H,3H)-dione(cas: 626-48-2).Quality Control of 6-Methylpyrimidine-2,4(1H,3H)-dione

The Article related to fluorination uracil green chem water, General Organic Chemistry: Synthetic Methods and other aspects.Quality Control of 6-Methylpyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 22, 2019, Shen, Lianbing; Chen, Yongqiang; Zhou, Yiping; Zhang, Anlian published a patent.Product Details of 23256-42-0 The title of the patent was Easily soluble compound sulfachloropyridazine sodium powder. And the patent contained the following:

The invention discloses a soluble compound sulfachloropyridazine sodium powder with high water solubility and good quality. The compound sulfachloropyridazine sodium powder comprises the following raw materials: sulfachloropyridazine sodium, trimethoprim and D-sucrose. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Product Details of 23256-42-0

The Article related to solubility sulfachloropyridazine sodium, Pharmaceuticals: Formulation and Compounding and other aspects.Product Details of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Zheng, Xing-xing; Ouyang, Wu-qing published an article in 2016, the title of the article was Preparation of erythromycin nanoemulsion and determination of its bacteriostatic activity in vitro.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate And the article contains the following content:

[Objective] To prepare erythromycin nanoemulsion, and to research its bacteriostatic activity in vitro. [Method] The preparation of the erythromycin nanoemulsion was optimized by studying the pseudoternary phase diagram. Broth dilution method was used to determine the MIC and MBC of erythromycin nanoemulsion on enteropathogenic Escherichia coli, Staphylococcus aureus, Pneumococcus and Proteus. [Result] The mass fraction of the components in erythromycin nanoemulsion included 2.8% erythromycin, 0.6% trimethoprim lactate, 35.2% EL-40, 7.5% cinnamaldehyde, and 53.9% distilled water. The susceptibility test revealed that the MIC of erythromycin nanoemulsion on enteropathogenic E. coli, S. aureus, Pneumococcus and proteus was 4, 1, 2 and 4μg/mL, resp. Their antibacterial effects significantly was better than other drugs. [Conclusion] The erythromycin nanoemulsion is successfully prepared, and its antibacterial effect in vitro is remarkable. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to erythromycin nanoemulsion bacteriostatic, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 27, 2020, there was a patent about bos taurus.Product Details of 23256-42-0 The title of the patent was Tilmicosin premix powder veterinary drug. And the patent contained the following:

The invention belongs to the tech. field of veterinary medicine. The title powder consists of tilmicosin, trimethoprim lactate, and anhydrous glucose. The combination of tilmicosin and synergist is adopted to enhance the treatment effect of the integral powder, and can be used for treating infectious pleuropneumonia, plague, lung disease and the like of pigs or cattle. After oral administration, the medicine is fast to absorb, and is characterized by strong tissue penetrating power, high concentration in lung and long effective blood concentration maintaining time. The medicine is stable, the preparation process is simple, and the use is convenient. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Product Details of 23256-42-0

The Article related to tilmicosin premix powder veterinary drug, Pharmaceuticals: Formulation and Compounding and other aspects.Product Details of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On March 27, 2020, there was a patent about bos taurus.Related Products of 23256-42-0 The title of the patent was Method for preparing veterinary tilmicosin premix powder drug. And the patent contained the following:

The invention belongs to the field of veterinary medicine technol. The title method comprises the following steps: crushing and sieving tilmicosin, trimethoprim lactate and anhydrous glucose, resp., weighing two raw materials of tilmicosin and trimethoprim lactate, adding anhydrous glucose, premixing, and adding anhydrous glucose, and fully mixing. The combination of the tilmicosin and the synergist is adopted to enhance the treatment effect of the integral powder, and can be used for treating infectious pleuropneumonia, plague, asthma and the like of pigs or cattle. After oral administration, the medicine is fast to absorb, and is characterized by strong tissue penetrating power, high concentration in lung and long effective blood concentration maintaining time. The preparation is stable, the preparation process is simple, and the use is convenient. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Related Products of 23256-42-0

The Article related to veterinary tilmicosin premix powder drug, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 9, 2011, Xu, Kefu published a patent.Application of 23256-42-0 The title of the patent was Medical composition for treating bacterial infection in digestive tract of poultry and its formulation. And the patent contained the following:

The title medical composition is composed of florfenicol 5-15, sulfamonomethoxine sodium 5-15, taurine 5-15, trimethoprim lactate 1-3, NaCl 5, KCl 5%, and addnl. anhydrous glucose. The medical composition is prepared by grinding the raw materials except for anhydrous glucose through 5# sieve resp., mixing uniformly, and adding anhydrous glucose. The medical composition may be used to prepare the medical preparations treating bacterial infection in digestive tract of poultry, with good synergistic effect, no side effect and definite and stable therapeutic effect. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Application of 23256-42-0

The Article related to bacterial infection digestive tract poultry, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia